AGN:CSE; AGNPF:OTCQB; AGN0:XFRA

Algernon Pharmaceuticals Inc.

Algernon is a Canadian clinical stage drug development company investigating multiple drugs with global unmet medical needs. Algernon has active research programs for idiopathic pulmonary fibrosis (“IPF”) with chronic cough, chronic kidney disease, and a psychedelic program investigating a proprietary form of DMT for stroke. Two of Algernon’s lead drugs are based on drug repurposing and the third compound is a naturally occurring psychedelic drug.

Drug repurposing offers several benefits over traditional drug development including a reduction in investment and risk (repurposed compounds have a much lower risk of failing in human trials as a result of safety issues), shorter research periods and a longer active patent life. Our program specifically investigates compounds that have never been approved in the U.S. or Europe.

We protect our lead compounds with method of use, dosing, and new formulation patents, as well as composition of matter patents that include derivatives and analogues. The Algernon model is highly capital efficient, and the company has assembled an experienced management team, a globally recognized medical and scientific advisory board, and a business advisory board.

AGN:CSE AGNPF:OTCQB AGN0:XFRA

View Company News

Visit Company Website

Expert Comments:

Douglas Loe, Leede Jones Gable

(1/13/23)

"Algernon Pharmaceuticals Inc. intends to initiate a 180-patient Phase 2b trial assessing the company's lead N-methyl-D-aspartate receptor antagonist ifenprodil/NP-120 as a treatment for chronic cough. The firm intends to commence the trial by Q3/23."

Tech. Analyst Says Pharma Co. Is at a Favorable Risk/Reward Ratio
(12/28/22)

Clive Maund, CliveMaund.com

(12/21/22)

"Algernon Pharmaceuticals Inc. has two things going for it. One is that it could come out with positive news at any time that could get the stock moving, and the other is that with only 2.3M shares in issue, when it does move, it is likely to result in big percentage gains. . .the company is therefore rated a Strong Speculative Buy."

Why One Fund Owns 13% of This Small-Cap Pharma
(12/12/22)

Dr. André Uddin, Research Capital Corporation

(11/30/22)

"Positive Phase 2a data was previously achieved with Algernon Pharmaceuticals Inc.'s ifenprodil in idiopathic pulmonary fibrosis and chronic cough. . .we believe management is going to hone most of its efforts on its lead candidate ifenprodil for chronic cough and advance it into Phase 2b trials."

Expert Says Buy Pharma Co. Stock 'as Soon as Possible'
(10/25/22)

Algernon Pharmaceuticals has entered into a clinical trial agreement with Yale and caught expert Clive Maund's attention. In light of this, Maund reviews the company's chart to tell you when he believes you should buy it.

Clive Maund, CliveMaund.com

(10/24/22)

"Algernon Pharmaceuticals Inc. got sold down further than we expected, making an unexpected further drop last week that took it down close to a trend line connecting a series of lows; however the company now looks set to reverse to the upside, especially as this morning it came out with the news that it has entered into a clinical trial agreement with Yale University for a DMT Phase 2 depression study. . .anyone holding should therefore stay long, and Algernon is rated a Buy again here."

Clive Maund, CliveMaund.com

(10/16/22)

"Algernon Pharmaceuticals Inc. has reacted back further than expected with the result that it has arrived back in a zone of strong support where a string of bullish candles has formed since early this month. It is deeply oversold here on its moving average convergence-divergence (MACD) and relative to its moving averages, with the normalizing MACD histogram (bars) calling for a rally soon, especially as we have only seen upside volume in recent days. . .the company is rated an immediate Strong Buy."

Clive Maund, CliveMaund.com

(9/27/22)

"One stock viewed as an Immediate Buy here is Algernon Pharmaceuticals Inc. Although it has reacted back heavily in recent weeks following a very strong runup, the reaction is within normal parameters, especially given what happened to the market as a whole; this reaction has brought it back into a zone of support near to its rising 50-day moving average, so that even a minor relief rally in the broad market could see it shoot back up again."

More Expert Comments

Clive Maund, CliveMaund.com (8/23/22) "Algernon Pharmaceuticals Inc. announced the successful closing of its financing, which was oversubscribed. This will lift a restraint from the stock price. . .the company's largest shareholder has upped its stake significantly so that it now owns over 13% of the stock, which is of course a vote of confidence. . .so the case for buying Algernon here could scarcely be stronger. . .this is definitely a stock that is worth going overweight on."

Clive Maund, CliveMaund.com (8/17/22) "Given the bright fundamentals, Algernon Pharmaceuticals Inc.'s reaction earlier this week is thought to be about over. . .it is a good time to make fresh purchases as the company is rated Buy again here."

Clive Maund, CliveMaund.com (8/15/22) "There is a quite compelling reason to hold out for further gains with Algernon Pharmaceuticals Inc. . .with a relatively tiny number of shares in issue, now believed to be at 1.9M, the company has the capacity to make really big moves, such as occurred last January, which move we traded, so it could continue to spike higher, resistance or not."

Clive Maund, CliveMaund.com (7/28/22) "Algernon Pharmaceuticals Inc. came out with very good news this morning that the data from its Phase 2 study of ifenprodil is much better than expected. This is thought likely to get the stock moving again, and so we are considered to be at another good buy spot here."

	Dr. André Uddin, Research Capital Corporation (7/28/22) "After conducting additional statistical review of the Phase 2a data in idiopathic pulmonary fibrosis (IPF) patients with chronic cough, key opinion leader Dr. Jacky Smith noted that Algernon Pharmaceuticals Inc.'s cough data showed a significant improvement in mean objective 24-hour and waking cough counts after four and 12 weeks. . .it is our belief that it would be logical to develop ifenprodil for two indications: in IPF patients and also in IPF patients who have chronic cough."

Dr. André Uddin, Research Capital Corporation (7/18/22) "Algernon Pharmaceuticals Inc. reported topline results of a Phase 2a trial with ifenprodil in idiopathic pulmonary fibrosis (IPF) patients with chronic cough. The IPF data hit its endpoint, showing promising initial efficacy. . .we recommend investors with a higher risk tolerance to aggressively purchase the stock."

Clive Maund, CliveMaund.com (6/1/22) "Algernon Pharmaceuticals Inc. is at a very good price and looks like it is shaping up for a breakout into a new bull market. This is a stock that is made much more attractive by the fact that it only has about 1.6M shares in issue as a result of a recent 1 for 100 share rollback. . .the stock is only at about 6% of the price at its 2016 peak."

Clive Maund, CliveMaund.com (2/2/22) "We can see entry and exit points on the latest three-month chart of Algernon Pharmaceuticals Inc. stock and how it has reacted back in a satisfactory manner to another good buy spot, with the technical setup now very positive. The time has thus arrived to buy back the position we sold at a much higher price; it is rated a Strong buy again here, especially as the broad stock market is on the up again."

	Dr. André Uddin, Research Capital Corporation (1/28/22) "For Algernon Pharmaceuticals Inc., the results of the ongoing Phase 2a trial in idiopathic pulmonary fibrosis/chronic cough (Q2/22) represent an important near-term catalyst investors should watch. . .we believe the company is back on track and focused on developing its pipeline. We consider Algernon's current valuation favorable from a risk-reward standpoint."

Clive Maund, CliveMaund.com (1/19/22) "As we can see on its latest six-month chart, Algernon Pharmaceuticals Inc.'s stock has soared. . .we have certainly done well with this, having about doubled our money in a month."

	Bob Moriarty, 321 Gold (1/18/22) "Algernon Pharmaceuticals Inc. has a lot of potential, and I placed my bet with shares bought in the open market. . .the company has a lot of good things in the works, and there should be a constant flow of news. It's the kind of company that could be a $500M market cap in a takeout after success in any one of several drug trials."

Clive Maund, CliveMaund.com (1/12/22) "Long-term charts show Algernon Pharmaceuticals Inc. stock to be very cheap. As it now has only 1.6M shares in issue after a 1 for 100 rollback, it has big upside potential. . .the company remains a Buy here and especially on any minor dips, if any."

Clive Maund, CliveMaund.com (12/22/21) "Algernon Pharmaceuticals Inc. stock has now arrived at what looks like a long-term cyclical low at the support at its late 2019 lows, which is a good point for it to turn, and that's what it looks like it is in the process of doing. . .the fundamentals of the company are believed to be positive. The conclusion is that Algernon is rated an attractive Speculative Buy here."

Clive Maund, CliveMaund.com (12/12/21) "Algernon Pharmaceuticals Inc. has some good things going on. The stock looks like it is at or close to a cyclical low, especially as volume has built up dramatically over the past month in a manner that is characteristic of a bottom, with upside volume kicking in in recent days. . .we could soon see some good gains in this stock."

	Dr. André Uddin, Research Capital Corporation (12/6/21) "Algernon Pharmaceuticals Inc.'s Ifenprodil is in a Phase 2a trial in idiopathic pulmonary fibrosis/chronic cough. . .the company expects to complete patient enrollment of the study by 2021E, with results anticipated in Q2/22. . .Algernon is a Phase 2-stage drug development company, yet it has a market cap of CA$7M. We believe its risk/reward profile is attractive."

Dr. André Uddin, Research Capital Corporation (8/4/21) Algernon Pharmaceuticals Inc. has decided to terminate the development of Ifenprodil for COVID-19. . .we agree with management that the risk-benefit profile of the COVID-19 program does not justify its continuation; we view the company's move as wise. . .Algernon is switching focus to the idiopathic pulmonary fibrosis/chronic cough indication."

Sam Riches, Weekend Dispensary (5/22/21) "Algernon Pharmaceuticals Inc. says it received positive feedback from the U.S. Food and Drug Administration (FDA) regarding its planned Phase 1 clinical trial, which is set to begin later this year with the U.K.-based Hammersmith Medicines Research. . .Algernon believes its approach could potentially lead to a breakthrough therapy designation from the FDA, which enables priority review and can fast track the clinical trial process."

	Dr. André Uddin, Research Capital Corporation (5/10/21) "Algernon Pharmaceuticals Inc. has recently filed an end-of-Phase 2 meeting request with the U.S. Food and Drug Administration to discuss advancing ifenprodil to the Phase 3 part of the Phase 2b/3 trial in COVID-19. . .ifenprodil is in a Phase 2a trial in idiopathic pulmonary fibrosis/chronic cough, for which results are expected in H2/21. DMT, a repurposed psychedelic compound, is expected to enter into a Phase 1 trial in stroke in H2/21."

Experts Following This Company

Gerard Adams, President & CEO – National Inflation Association
	Douglas Loe, Managing Director & Analyst, Healthcare and Biotechnology – Leede Jones Gable
Clive Maund – CliveMaund.com
	Chris Temple, Editor and Publisher – The National Investor
	Dr. André Uddin – Research Capital Corporation

Company News

3/2/2023 – Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board

2/28/2023 – Algernon Pharmaceuticals Announces 4 for 1 Forward Share Split

2/21/2023 – Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor

2/17/2023 – Algernon Pharmaceuticals subsidiary completes first dosing in Phase 1 clinical study of DMT

2/16/2023 – Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase

1/17/2023 – Algernon Pharmaceuticals subsidiary Algernon NeuroScience doses first patient in stroke study

1/17/2023 – Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

1/11/2023 – Algernon Pharmaceuticals Looks to Advance DMT Stroke Research

1/11/2023 – Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

1/10/2023 – Algernon Pharmaceuticals releases details of Phase 2b chronic cough study of Ifenprodil

1/9/2023 – Algernon Pharmaceuticals Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil

1/4/2023 – Algernon Pharmaceuticals forms Algernon NeuroScience subsidiary to advance DMT stroke program

1/3/2023 – Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company's Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.See disclaimer for more details.

Streetwise Company Fact Sheet

Algernon Pharmaceuticals Inc.

(AGN:CSE - AGNPF:OTCQB - AGN0:XFRA)

2023/3/20 3:24:54

Analyst coverage

Leede Jones Gable — Douglas Loe

Research Capital Corporation — Dr. André Uddin

Newsletter coverage

—

Company News

View Latest News

Streetwise Reports Articles

12/28/2022 - View Article

12/12/2022 - View Article

10/25/2022 - View Article

09/13/2022 - View Article

09/04/2022 - View Article

Streetwise - Algernon Pharmaceuticals Inc. Ownership Overview*

Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA)

^*Share Structure as of 1/20/2023

Investing Highlights

	Advancing new drug treatments for billion dollar global disease markets.
	Conducting multiple phase II clinical trials
	Experienced management team & globally recognized medical advisory board

catalyst Calendar

Q1 2023	Begin Phase 1 Bioequivalence Study for New Once-Daily Formulation \| IPF / COUGH
Q2 2023	US FDA IND filing / Fast Track Application \| IPF / COUGH
Q2 2023	Begin Phase 2b Study \| IPF / COUGH
Q2 2023	Phase 1 DMT Data \| DMT/ STROKE
Q2 2023	Begin Phase 1 Study \| CKD
Q4 2023	Phase 1 CKD Data